Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
University of California, Davis Comprehensive Cancer Center, Sacramento, California Smilow Cancer Hospital (Yale University), New Haven, Connecticut Florida Cancer Specialists, Sarasota, Florida Lee Moffitt Cancer Center, Tampa, Florida Johns Hopkins University, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts NYU Langone, New York, New York Memorial Sloan Kettering Cancer Center, New York, New York Duke Cancer Center, Durham, North Carolina Carolina BioOncology Institute, Huntersville, North Carolina The Christ Hospital, Cincinnati, Ohio Sarah Cannon Research Institute, Nashville, Tennessee Sarah Cannon Research Institute at Mary Crowley, Dallas, Texas University of Texas, MD Anderson Cancer Center, Houston, Texas START, San Antonio, Texas NEXT Oncology Virginia, Fairfax, Virginia